Amersham is a world leader in medical diagnostics and in life sciences. Headquartered in the UK, the company employs 10, 000 people worldwide and had sales of £1.62 billion in 2002. Amersham shares (AHM) are traded on the London, New York and Oslo stock exchanges and we are part of the FTSE Index of Britain’s 100 leading public companies.

Amersham has three main business areas: Medical Diagnostics, operating as Amersham Health, and Protein Separations and Discovery Systems, serving the market as Amersham Biosciences.

In our 2002 Annual Report we explained our business model, and how the three parts of our business are working more closely together to change the way medicine will be delivered in the future.

In this Interim Report, we focus on the impact of our innovations here and now. With examples drawn from each of our business areas, we’ll show you how our transformational technologies are bringing important benefits to patients – enabling disease to be better understood, diagnosed earlier and treated more effectively.